SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership aimed at significantly reducing production costs and expanding capacity, which has driven substantial intraday stock volatility. The community is actively discussing the stock's low float and high trading volume, fueling speculation about a potential short squeeze and anticipating further upward movement as it tests key resistance levels. This partnership is seen as a crucial step for scaling their fingerprint drug screening technology ahead of anticipated future market expansion.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending due to recent discussions surrounding its integration as a fuel-discount token within the EzFill app, generating buzz about its expanding utility. The community is sharply divided, with many anticipating significant future appreciation from multi-year lows and viewing it as "digital silver," while others express frustration over its recent price action and struggle to overcome key resistance levels.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is currently a focal point for year-end tax loss selling, leading to sharp price movements and a polarized community discussion. Many foresee further declines for the meme coin, while a resilient group of long-term holders views the current dip as a strategic accumulation opportunity for future crypto cycles, with eyes on a potential rally in 2026.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending significantly following the FDA approval of NEREUS, marking the first new pharmacologic treatment for motion-induced vomiting in over four decades. The community is actively discussing the drug's potential beyond motion sickness, particularly its vast opportunity in addressing GLP-1 induced nausea, which many see as a transformative revenue driver for the company. With analysts raising price targets and whispers of potential buyout interest, investors anticipate continued upside as the market fully prices in this key regulatory win and the company's robust pipeline.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp (ESHA) is trending within a volatile low-float SPAC sector, fueled by discussions surrounding its extremely tight share float and high insider ownership. The community is actively debating its potential for rapid price movement and a short squeeze, drawing comparisons to other recently surging SPACs as new utility via a planned reward token is also highlighted.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics (CORT) is trending with significant volatility after receiving an FDA Complete Response Letter for its relacorilant drug, triggering a sharp decline in shares. The community is fiercely divided, with many calling the sell-off an overreaction given the company's existing profitable drug and deep pipeline, while others foresee further downside following analyst downgrades and a need for more clinical evidence. This binary regulatory event has intensified speculation, as investors weigh potential recovery against lingering uncertainty.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending following the FDA's acceptance and priority review of AXS-05 for Alzheimer's disease agitation, alongside positive feedback supporting an upcoming NDA for AXS-12 in narcolepsy. The market is reacting strongly to this dual pipeline advancement, with community members expressing high optimism and noting significant short-covering as a key driver of the momentum.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after a competitor's drug for Cushing's syndrome received a regulatory setback from the FDA, which the community views as a significant advantage for Xeris's approved treatment, Recorlev. This development is seen as clearing the path for Recorlev to gain market share, fueling discussions among investors about the company's long-term growth potential and undervaluation, supported by positive analyst outlooks.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is highly active following the CME Group's recent, repeated increases in margin requirements for silver futures, sparking intense debate among traders who see it as a desperate measure to control a surging market. This volatility is further fueled by conflicting narratives around impending Chinese silver export restrictions and the growing disconnect between paper and physical prices. The community is sharply divided between those predicting a massive short squeeze driven by industrial demand and global supply shifts, and those anticipating a significant pullback.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as its community intensely debates future prospects amid persistent price challenges. Significant anticipation surrounds potential regulatory clarity from the "Clarity Act" and major developments like integrations with large retailers and payment networks. Despite widespread frustration over price action, many remain bullish, highlighting AMP's core utility in secure digital payments and its existing merchant adoption as crucial for eventual upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Baytex (BTE) Upgraded to Strong Buy: What Does It Mean for the Stock?

Baytex (BTE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

New Strong Buy Stocks for December 31st

BTE, BHP, IOT, GTLB and CMI have been added to the Zacks Rank #1 (Strong Buy) List on December 31st, 2025.

Best Value Stocks to Buy for December 31st

MMS, VIRT and BTE made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 31, 2025.

Baytex Energy (OTCMKTS:BTEGF) Trading Up 1.6% - Here's What Happened

Baytex Energy (OTCMKTS:BTEGF) Stock Price Up 1.6% - Here's Why...

Mark Bly Acquires 20,000 Shares of Baytex Energy (TSE:BTE) Stock

Baytex Energy Corp. (TSE:BTE - Get Free Report) (NYSE:BTE) Director Mark Bly acquired 20,000 shares of the business's stock in a transaction dated Wednesday, December 24th. The stock was bought at an...

Baytex Energy (TSE:BTE) Director Mark Bly Purchases 20,000 Shares

Baytex Energy Corp. (TSE:BTE - Get Free Report) (NYSE:BTE) Director Mark Bly bought 20,000 shares of the business's stock in a transaction dated Wednesday, December 24th. The stock was bought at an...

TD Securities Raises Baytex Energy (TSE:BTE) Price Target to C$5.00

TD Securities boosted their target price on Baytex Energy from C$4.75 to C$5.00 and gave the stock a "buy" rating in a research report on Tuesday...

Is Baytex Energy (BTE) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BTE or CNQ? Canada's Oil Investors Weigh 2026 Trade

BTE's streamlined strategy, rising cash flows, and earnings momentum make it stand out against steady CNQ heading into 2026.

<ul class="summary-bullets"><li>Baytex Energy announced a target of 3% to 5% annual production growth, targeted to reach about 75,000 boe/d in 2028.&nbsp;</li><li>The company said it plans to return a significant portion of Eagle Ford’s $2.14 billion in sale proceeds to shareholders.&nbsp;</li><li>It appointed Chad E. Lundberg as the President and Chief Operating Officer from Dec. 22, 2025.</li></ul><p>Baytex Energy Corp. (BTE) is setting the stage for growth in 2026 with a $625 million capital budget and plans to return a significant part of its Eagle Ford sale proceeds to shareholders. Additionally, the announcement of a new leadership signals a shift in priorities for the year ahead.</p><p>Shares of BTE climbed over 2% in Monday's pre-market trade.</p><h2 class="st-heading-2">Capital Budget Usage</h2><p>Baytex Energy announced a capital budget of $550 to $625 million for 2026, a target of 3% to 5% production growth reaching about 75,000 barrels of oil equivalent per day (boe/d) in 2028.</p><p>The company’s 2026 exploration and development budget aims to generate an average annual production of 67,000 to 69,000 boe/d and is expected to deliver 3% to 5% production growth from 2025 levels.</p><p>Of this, about 55% of the budget will be allocated to light oil assets, and the remaining 45% to heavy oil assets, the company said. Production in the first quarter (Q1) of 2026 is expected to average 68,000 to 69,000 boe/d, with plans to scale to 70,000 boe/d at the end of the year. The company also plans to bring 91 heavy-oil wells onstream, with 2026 production averaging 43,000 to 44,000 bbl/d.</p><p>Of the total capital expenses, $50 to $75 million growth capital will be focused on the Pembina Duvernay and northeast Alberta Mannville, $50 million will be directed towards infrastructure investment that will include anchor oil batteries and water infrastructure in the Pembina Duvernay, and gas conservation in Peace River, and another $50 million will go towards exploration and land investments, the company said.</p><p>"Looking ahead, we are targeting 3% to 5% annual production growth while investing in exploration and infrastructure for future development. Supported by our industry-leading net cash balance sheet, we are prioritizing shareholder returns in 2026," Eric T. Greager, Chief Executive Officer of Baytex Energy, said.</p><h2 class="st-heading-2">Sale Proceeds And Executive Charges</h2><p>Baytex Energy completed the sale of its U.S. Eagle Ford Assets for $2.14 billion on December 19, and plans to return a significant portion of the proceeds to shareholders.</p><p>The company also reaffirmed its annual dividend guidance of $0.09 per share, subject to Board of Directors approval.</p><p>Additionally, the energy company announced that Chad E. Lundberg will take over as President and Chief Operating Officer from Dec. 22, 2025.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around BTE stock remained in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels at the time of writing.</p><figure class="image"><img style="aspect-ratio:1291/159;" src="https://news.stocktwits-cdn.com/Baytex_sentiment_png_47e2fce461.webp" alt="On Stocktwits, retail sentiment around BTE stock remained in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels at the time of writing." width="1291" height="159"></figure><p>Shares of BTE have gained over 25% in the past one year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

CANADA - 2025/09/17: In this photo illustration, the Baytex Energy Corp. logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Baytex Energy Sets 2026 Capital Spending, Growth Targets – And Names New COO

The company announced a capital budget of up to $625 million for 2026, with 55% allocated to light oil assets and 45% to heavy oil assets.

Equity

Baytex Energy Corp. operates as an oil & gas exploration and production company. It engages in the acquisition, development and production of crude oil and natural gas in the Western Canadian Sedimentary Basin and in the Eagle Ford in the United States. The company was founded on June 3, 1993 and is headquartered in Calgary, Canada.

BTE
Baytex Energy Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BTE News

BTEBaytex Energy Corp.